Share class: Gilead Sciences, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A11,246,265,8571,244,733,708 ( 99.88 %) 0 99.88 %

Major shareholders: Gilead Sciences, Inc.

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.255 %
115,342,884 9.255 % 10 654 M $
BlackRock Advisors LLC
7.104 %
88,538,676 7.104 % 8 178 M $
Capital Research & Management Co. (World Investors)
6.142 %
76,548,928 6.142 % 7 071 M $
Capital Research & Management Co. (Global Investors)
4.959 %
61,799,671 4.959 % 5 708 M $
State Street Corp.
4.828 %
60,171,691 4.828 % 5 558 M $
Wellington Trust Co., NA
2.776 %
34,600,676 2.776 % 3 196 M $
Fidelity Management & Research Co. LLC
2.656 %
33,102,805 2.656 % 3 058 M $
Dodge & Cox
2.652 %
33,045,737 2.652 % 3 052 M $
Ishares (DE) InvAG mit Teilgesellschaftsvermogen
2.396 %
29,860,653 2.396 % 2 758 M $
Geode Capital Management LLC
2.21 %
27,540,870 2.21 % 2 544 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
BRAM - Bradesco Asset Management SA DTVM
0.000205 %
5,110 0.000205 % 233 816 $

Breakdown by shareholder type

Institutional69.24%
Other8.45%
State Street Corp.4.83%
Manulife Financial Corp.0.51%
Schweizerische Nationalbank0.3%
Sumitomo Mitsui Trust Group, Inc.0.24%
Governments0.2%
Raymond James Financial, Inc.0.18%
Swedbank AB0.17%
SEI Investments Co.0.11%
Individuals0.09%
Skandinaviska Enskilda Banken AB0.06%
The Bank of Nova Scotia0.06%
Banco Bilbao Vizcaya Argentaria SA0.05%
Corebridge Financial, Inc.0.03%
Fifth Third Bancorp0.02%
Zurich Insurance Group AG0.02%
ING Groep NV0.02%
Banque Cantonale Vaudoise0.01%
Cadence Bank0.01%
Zions Bancorporation NA0.01%
Atlantic Union Bankshares Corp.0.01%
Ally Financial, Inc.0.01%
Unknown15.37%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 66.66%
United Kingdom 4.87%
Germany 2.69%
Canada 1.8%
Norway 1.57%
Australia 1.27%
France 1.14%
Switzerland 0.65%
Sweden 0.62%
Japan 0.47%
Netherlands 0.45%
South Korea 0.39%
Hong Kong 0.34%
Ireland 0.23%
Denmark 0.23%
Luxembourg 0.22%
Belgium 0.19%
Spain 0.16%
Italy 0.14%
Austria 0.1%
Individuals 0.09%
China 0.08%
Taiwan 0.07%
Finland 0.07%
Czech Republic 0.03%
Singapore 0.02%
India 0.02%
New Zealand 0.02%
Slovenia 0.01%
South Africa 0.01%
Mexico 0.01%
Liechtenstein 0.01%

Based on 1000 largest holdings

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Employees
18,000
Calendar
More about the company